Evaluating bempedoic acid for the treatment of hyperlipidaemia by Penson, P et al.
 Penson, P, McGowan, M and Banach, M
 Evaluating bempedoic acid for the treatment of hyperlipidaemia
http://researchonline.ljmu.ac.uk/5225/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Penson, P, McGowan, M and Banach, M (2017) Evaluating bempedoic acid 
for the treatment of hyperlipidaemia. Expert Opinion on Investigational 
Drugs. ISSN 1744-7658 
LJMU Research Online
 1 
REVIEW 
 
Evaluating bempedoic acid for the treatment of hyperlipidaemia 
 
Peter Penson1, Mary McGowan2,3, Maciej Banach4-6* 
 
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, 
UK; 2Esperion Therapeutics, Inc., Ann Arbor, MI, USA; 3 Section of Cardiology, Dartmouth-
Hitchcock Heart & Vascular Center, Lebanon, NH;4Department of Hypertension, Chair of 
Nephrology and Hypertension, Medical University of Lodz, Poland; 5Healthy Aging Research 
Centre (HARC), Lodz, Poland; 6Polish Mother’s Memorial Hospital Research Institute, Lodz, 
Poland. 
 
 
 
*Corresponding author: Prof. Maciej Banach, MD, PhD, FNLA, FAHA, FESC, FASA, Head, 
Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, 
Zeromskiego 113; 90-549 Lodz, Poland. Phone: +48 42 639 37 71; Fax: +48 42 639 37 71;E-
mail: maciejbanach@aol.co.uk 
 
 
Conflict of Interest Disclosures: None 
 
Number of words: 4331  
 2 
ABSTRACT: 
Introduction: Despite the effectiveness of statins in the treatment of lipid disorders, residual risk 
still exists, and hitherto studies where additional drugs were added to statin therapy have been 
mainly negative or the outcomes were very modest. Therefore there is still a need for new and 
effective oral agents in the combination therapy of lipid disorders.  
Areas Covered: The review covers the current state of knowledge on the mechanism of action of 
bempedoic acid (ETC-1002) and results from recent clinical studies. 
Expert Opinion: ETC-1002 is a novel oral lipid-lowering therapy. The reduction of both low-
density lipoprotein cholesterol (LDL-C) and high sensitivity C-reactive protein (hsCRP) 
demonstrated by ETC-1002 in clinical trials suggests that agent may have the potential for CV risk 
reduction. Adverse effects of current lipid-lowering agents can be dose-limiting, and combination 
approaches to lipid-lowering may often be utilized for optimal CV risk reduction. Because of this, 
new lipid-modulating drugs are urgently required. ETC-1002 has a unique mechanism of action 
(adenosine triphosphate-citrate lyase inhibition). It has been shown to be safe in combination with 
statins as well as ezetimibe, and appears to effectively lower LDL-C and has the potential to reduce 
the risk of muscle-related adverse events, which can limit the utilization and effectiveness of statin 
therapy.  
 
Keywords: ETC-1002, Bempedoic acid, hyperlipidaemia, atherosclerosis, cardiovascular disease.  
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ARTICLE HIGHLIGHTS: 
1. Bempedoic acid (ETC-1002) is a novel lipid-lowering drug with a unique mechanism of action.  
2. Bempedoic acid is a prodrug of bempedoic acid-CoA, which reduces cholesterol production 
by inhibition of adenosine triphosphate-citrate lyase. Conversion of bempedoic acid to the 
active form occurs preferentially in the liver.  
3. Bempedoic acid reduces LDL-C in a wide variety of hypercholesterolaemic populations 
including patients with cardiovascular disease (CVD), type 2 diabetes, mildly elevated blood 
pressure, elevated and normal triglyceride concentrations 
4. In all studies to date, bempedoic acid has been shown to reduce hsCRP, a marker of 
inflammation with respect to CVD. 
5. Bempedoic acid has an additive effect upon LDL-C lowering when combined with existing 
lipid-lowering agents (ezetimibe and statins). 
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Drug Summary: 
Drug Name: Bempedoic acid 
Phase: 2-3 
Indication: Hyperlipidaemia 
Mechanism of 
Action: 
Inhibition of adenosine triphosphate-citrate lyase 
Route of 
Administration: 
Oral 
Chemical 
Structure: 
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid 
 
Pivotal trials: ETC1002-040 (NCT02666664, Ongoing) Randomized Controlled 
Cardiovascular outcomes trial with approximately 1950 participants 
 
ETC1002-043 (Planned) Randomized Controlled Cardiovascular 
outcomes trial with approximately 12600 participants 
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ABBREVIATIONS: 
 
ACL   Adenosine triphosphate-citrate lyase 
ACS   Acyl-CoA synthetase 
ACSVL1  Very long-chain acyl-CoA synthetase 
ASCVD  Atherosclerotic cardiovascular disease 
CLEAR Cholesterol Lowering via BEmpedoic acid, an ACL-inhibiting Regimen 
CHD Coronary Heart Disease 
CV Cardiovascular 
CVD Cardiovascular disease 
CVOT Cardiovascular outcomes trial 
EMA European Medicines Agency 
FDA (United States) Food and Drug Administration 
HDL-C  High-density lipoprotein cholesterol 
HeFH   Heterozygous familial hypercholesterolemia  
hsCRP   High sensitivity C-reactive protein 
LDL-C  Low-density lipoprotein Cholesterol 
Lp(a)   Lipoprotein(a) 
Non-HDL-C   Non-high-density lipoprotein cholesterol 
PCSK9  Proprotein convertase subtilisin/kexin type 9 
PCSK9i  Proprotein convertase subtilisin/kexin type 9 inhibitor 
SWOT   Strength, Weakness, Opportunity, Threat 
TC   Total cholesterol 
TG   Triglycerides   
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1. Overview of the market 
Reduction in risk of cardiovascular disease (CVD) morbidity and mortality via reduction of low-
density lipoprotein cholesterol (LDL-C) has been shown to be effective in both primary [1] and 
secondary [2] prevention of CV events [3]. This approach became possible with the introduction 
of statins, drugs that target the mevalonate pathway downstream of adenosine triphosphate-citrate 
lyase (ACL) by inhibition of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA 
reductase), the rate-limiting step in cholesterol biosynthesis. This has been a remarkably successful 
and consistent approach to cardiovascular disease risk reduction. The Cholesterol-Treatment 
Trialists’ collaborators performed a meta-analysis of 14 randomized controlled trials (RCTs) and 
concluded that lowering plasma concentrations of LDL-C by 1 mmol/L (38.7 mg/dl) reduced the 
risk of major coronary events by 23% over 5 years. The greatest benefit was seen in those who had 
had a previous cardiovascular (CV) event, but a substantial reduction in CVD was also observed 
in a primary prevention population [4].  
Recent developments have enabled more substantial reductions in plasma LDL-C, an approach 
that would appear to result in a further reduction of CV risk. The IMProved Reduction of 
Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) investigated combination therapy 
with simvastatin and ezetimibe in secondary prevention. The combination led to lower LDL-C 
levels (53.7 vs 69.5 mg/dL) than simvastatin monotherapy, and importantly this translated to 
reduced risk of the primary endpoint, which was a composite of cardiac events (hazard ratio [HR] 
0.936 [0.89 to 0.99]) [5]. However, surprisingly, despite these positive and significant results the 
US Food and Drug Administration (FDA) did not approve ezetimibe for use as an addition to statin 
therapy for reduction of CV events in patients with coronary heart disease (CHD) [6, 7].  
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A new class of lipid lowering agents, the proprotein convertase subtilisin/kexin type 9 
inhibitors (PCSK9-i) have recently been approved for LDL-C lowering in multiple countries.  
They show a substantial reduction in LDL-C levels. The ODYSSEY-LONG TERM trial, which 
recruited participants with heterozygous familial hypercholesterolemia (HeFH), CHD or a risk 
equivalent, demonstrated substantial reductions in LDL-C after treatment with alirocumab, a 
monoclonal antibody inhibitor of PCSK9 protein, when used with a statin [8, 9]. These LDL-C 
lowering results complement those of the OSLER study, which utilized evolocumab, another 
PCSK9 inhibitor [10]. Both studies showed significant reduction of CV events with PCSK9 
inhibitors (however it is worth mentioning that these studies were neither designed nor powered 
to investigate CV outcomes) and confirmed the safety of LDL-C reduction, to levels even below 
25 mg/dL [6, 7]. The results of the cardiovascular outcomes trials (CVOT) with these agents 
(FOURIER, ODYSSEY OUTCOMES) are expected in 2017 and 2018 [11, 12]. 
However, the effectiveness of LDL-C lowering therapy in clinical practice has been limited by 
a number of factors, including poor adherence to statin therapy, statin discontinuation [13] and 
statin intolerance [14] and residual risk despite achieving therapeutic LDL-C targets [6, 15]. Statin 
monotherapy or combinations of currently available drugs are unlikely to achieve optimal 
concentrations of LDL-C in all patients, especially those who are at high CV risk [16].  Despite 
the fact that statins are very well tolerated, they do have well documented adverse effects, mainly 
muscle-related adverse events, and PCSK9 inhibitors require subcutaneous injection, which may 
not be acceptable or convenient for all patients. Lipid reduction by ezetimibe as monotherapy is 
limited [17]. Thus, despite the benefits conferred by these drugs, there is an urgent clinical need 
for new LDL-C lowering therapies, which can be demonstrated to significantly reduce elevated 
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LDL-C levels and limit adverse effects, either as monotherapy or in combination with existing 
drugs. Bempedoic acid shows early promise in this regard. 
 
2. Introduction to Bempedoic Acid 
Bempedoic acid (8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid, ETC-1002, 
developed by Esperion Therapeutics Inc., is a novel lipid regulating drug with a unique mechanism 
of action. It is a prodrug that is converted to bempedoic acid-CoA - a competitive inhibitor of the 
enzyme ACL. Conversion of bempedoic acid to the active form (ETC-1002 CoA) occurs 
preferentially in the liver [18]. ACL is the enzyme responsible for hepatic production of cytosolic 
acetyl-coenzyme A, the precursor of the mevalonate pathway of cholesterol biosynthesis. The 
predominant biochemical manifestation of bempedoic acid therapy is an increase in low density 
lipoprotein (LDL)-receptor activity and a subsequent reduction in plasma concentrations of LDL-
C [18]. 
The mechanism of action of bempedoic acid, as understood from preclinical studies and the 
results of clinical trials, was extensively discussed in a review published in 2014 [19], and, more 
recently, presented at the Scientific Sessions of the American Heart Association in 2015. The 
definitive mechanism of action of bempedoic acid has just been published [20]. New clinical 
evidence and an improved understanding of the mechanism of action of bempedoic acid have 
provoked this update. We aim to give an overview of all aspects of this promising new agent, with 
a particular focus on the results of Phase 2 clinical trials and recent experimental studies. 
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2.1. Pharmacology and mechanism of action of bempedoic acid 
The predominant biochemical manifestations of bempedoic acid administration are an increase 
in LDL receptor activity and consequent reduction in the plasma concentration of LDL-C [18]. In 
relation to its LDL-C lowering effect, bempedoic acid is a prodrug of ETC-1002-Coenzyme A 
(ETC-1002-CoA). ETC-1002-CoA acts as a competitive inhibitor of the enzyme adenosine 
triphosphate-citrate lyase and reduces the production of cytosolic acetyl-coenzyme A, the 
precursor of the mevalonate pathway of cholesterol biosynthesis [18]. ACL is a unique target for 
LDL-C and CV risk reduction because it produces precursors required for both fatty acid and 
cholesterol synthesis [21] (Figure 1). Genetic inhibition of ACL has been shown to up-regulate 
LDL receptor expression and activity in McArdle cells [18]. Polymorphisms of ACLY, the gene 
encoding ACL have been linked with varying growth traits in cattle [22] and altered plasma 
triglyceride responses to fish-oil supplementation in humans [23]. 
The mechanism by which bempedoic acid is converted to the active form, ETC-1002-CoA, 
has been extensively investigated in preclinical experiments [24]. It has been demonstrated that 
bempedoic acid is converted into ETC-1002-CoA by hepatic acyl-CoA synthetase (ACS) [18], a 
family of enzymes, which catalyse the CoA thioesterification of fatty acids and thereby regulate 
the distribution and trafficking of fatty acids into complex lipids [25]. In particular, very long-
chain acyl-CoA synthetase 1 (ACSVL1) has been identified as the specific isoform of ACS 
responsible for activation of bempedoic acid to ETC-1002-CoA [18]. ETC-1002-CoA formation 
correlates with ACSVL1 expression in human liver subcellular fractions, and genetic silencing of 
ACSVL1 with small interfering RNAs (siRNAs) has been shown to prevent formation of 
bempedoic acid-CoA in McArdle cells. ACSVL1 is highly expressed in human liver microsomes, 
only modestly expressed in kidney, and has not been detected in skeletal muscle cells [18]. Thus, 
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the distribution of ACSVL1 (and therefore the sites of ETC-1002-CoA activity) would appear to 
be ideal to allow perturbation of hepatic cholesterol synthesis, with minimal effects in other tissues 
[18]. In particular, the absence of ASCVL1 (and therefore ETC-1002-CoA) in skeletal muscle may 
allow effective LDL-C-lowering with reduced risk of muscle-related adverse events. These events 
have been associated with statin therapy, and may result from the depletion in skeletal muscle of 
mevalonate pathway products, downstream of HMG-CoA-reductase [26-29] 
 
3. Clinical efficacy and safety of bempedoic acid 
Clinical trials investigating the efficacy and safety of bempedoic acid have been conducted, or 
are ongoing in a variety of populations including patients with hypercholesterolaemia and either 
normal or elevated triglycerides [30,31], patients with hypercholesterolaemia and type 2 diabetes 
mellitus [32], patients with hypercholesterolaemia and statin intolerance [33], 
hypercholesterolaemia and hypertension [34].  Additionally, bempedoic acid has been studied in 
combination with statins [35,36] or ezetimibe [37] (Table 1). The overall Phase 3 program 
evaluating the safety and efficacy of bempedoic acid is referred to as the Cholesterol Lowering via 
BEmpedoic Acid, an ACL-Inhibiting Regimen (CLEAR).  Specifically, CLEAR Harmony (Study 
1002-040) is investigating the long-term safety of bempedoic acid in patients with atherosclerotic 
cardiovascular disease (ASCVD) and/or HeFH [38]. The effects of bempedoic acid on lipids and 
lipoproteins in phase 2 clinical studies reported to date are summarized below. 
 
 
3.1. Efficacy and safety of bempedoic acid in patients with elevated blood cholesterol and 
either normal or elevated triglycerides  
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Ballantyne et al. conducted a phase 2 clinical trial (ETC-1002-003, NCT01262638) to 
investigate the safety and efficacy of bempedoic acid in a group of 177 patients with normal (<150 
mg/dL) and elevated (150 to <400 mg/dL) triglycerides and hypercholesterolaemia who were 
randomized to receive placebo or bempedoic acid 40mg, 80mg or 120mg daily for 12 weeks [31]. 
The baseline characteristics of all groups were very similar: mean age 56-59 years, and baseline 
mean LDL-C was between 163 mg/dL and 170 mg/dL for all groups [31]. Treatment with 
bempedoic acid led to mean reductions of LDL-C by 26.62.2% in the 120mg bempedoic acid 
group compared to a 2.12.2% reduction in placebo, a statistically significant difference 
(p<0.001). The reduction in LDL-C appeared to occur in the first two weeks of treatment and to 
stabilize thereafter. Triglyceride status (normal or elevated) did not appear to influence LDL-C 
lowering [31]. Non-HDL-C and apolipoprotein B (apoB) reductions were similar in magnitude to 
LDL-C reductions; LDL particle number, an emerging marker of CV risk [39-42], decreased, and 
a statistically significant increase in HDL particle number was observed at the highest and lowest 
doses. Lipoprotein(a) [Lp(a)] did not appear to be altered by bempedoic acid. No safety concerns 
have emerged in this trial, or any other trial to date [31]. 
 
3.2. Bempedoic acid in patients with type 2 diabetes mellitus 
Gutierrez et al. assessed the efficacy and safety of bempedoic acid in patients with type-2 
diabetes mellitus (DMt2), a population at very high risk for developing CVD. The trial (ETC-
1002-005, NCT01607294) involved 60 DMt2 patients with hypercholesterolaemia who were 
randomised to receive placebo for four weeks or bempedoic acid (80mg/day for two weeks, then 
120 mg/day for 2 weeks) [32]. LDL-C was reduced by 39% (95% confidence interval [CI]: 46.2, 
31.7, p<0.0001) compared to placebo, reductions were also seen for non-HDL-C: 31.4% (38.0-
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24.8, p=0.0001) and total cholesterol (by 24.6%, 29.9-19.4, p<0.001) compared to placebo. 
Treatment with bempedoic acid was associated with a 40.5% median reduction in high sensitivity 
C-reactive protein (hsCRP), compared with 11.0% for placebo (p=0.0011). There was no 
statistically significant difference between groups in terms of HDL-C, triglycerides, free fatty acids 
or fasting insulin suggesting a neutral effect on these parameters. Additionally, unlike what has 
been seen in some statin studies [43,44] the impact of bempedoic acid on glucose was neutral [32].  
 
3.3.  Efficacy and safety of bempedoic acid in patients with statin intolerance 
Statin intolerance worsens therapy adherence, increases drug discontinuation and can limit the 
effectiveness of CV risk reduction [14,28,45] and thus, alternative strategies for lipid-lowering are 
required in patients who suffer adverse effects on statin therapy. Thompson et al. investigated the 
effects of bempedoic acid in 56 hypercholesterolaemic patients with statin intolerance (ETC-1002-
006, NCT01751984). Statin intolerance was defined as muscle-related adverse effects that 
occurred upon treatment with at least one statin which resolved within four weeks of 
discontinuation. The trial was conducted over 8 weeks. Patients were randomized to receive either 
placebo (n=19) or an initial dose of 60mg bempedoic acid, increased at 2 week intervals to reach 
a 240 mg daily dose (n=37) [33]. Consistent with previous studies, [31,32] bempedoic acid reduced 
LDL-C 28.7% more than placebo (95%CI: -35.4 to -22.1; p<0.0001). Similar statistically 
significant reductions in non-HDL-C and total cholesterol were observed. ApoB was reduced by 
19.7±2.6% in bempedoic acid treated patients compared with 4.4±3.8% in placebo (p=0.0019) 
[33]. And likewise, hsCRP was reduced significantly in the treated vs placebo group (p=0.0022). 
62% of patients randomized to bempedoic acid achieved LDL-C goals, compared with none in the 
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placebo group (p<0.0001). There was no statistically significant difference between the groups in 
terms of HDL-C, triglycerides, apoA-I, Lp(a) or free fatty acids.  
Adverse events were reported by 79% of patients treated with placebo, and 70% treated with 
bempedoic acid. These led to discontinuation in 16% of patients in the placebo group and 14% in 
bempedoic acid group. A similar percentage of placebo and bempedoic acid treated patients (32 
vs 27%) reported muscle adverse effects, and 16% of placebo treated patients withdrew due to 
muscle-related side-effects, whereas importantly there were no discontinuations because of 
muscle-related side effects in the bempedoic acid group [33]. 
 
3.4. Bempedoic acid and ezetimibe combined therapy 
Combination therapy with ezetimibe (which reduces cholesterol absorption by blocking 
Niemann-Pick C1-like 1 proteins on intestinal epithelial cells) [6] and bempedoic acid (which 
reduces hepatic cholesterol biosynthesis leading to up-regulation of the LDLR), is a rational multi-
target approach to lipid lowering. This tactic has been shown to lower LDL-C by up to 48%. 
Ezetimibe is commonly used in statin intolerant patients [46], however, its ability to lower LDL-
C as a monotherapy is limited. Thus the combined use of ezetimibe and bempedoic acid in statin 
intolerant patients has potential value in terms of improved LDL-C goal attainment.  
A study evaluating the combination of bempedoic acid (120 or 180 mg daily) with ezetimibe 
(10mg daily) was compared with monotherapy of each drug in a 12 week trial, which randomized 
349 patients, and included patients with good adherence to statin therapy and statin intolerant 
patients (ETC-1002-008, NCT01941836). In this study statin intolerance was defined as the 
inability to tolerate at least two statins, including one statin at the lowest approved dose due to 
muscle-related symptoms such as pain, aches, weakness, or cramping that began or increased 
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during statin therapy and resolved when statin therapy was discontinued.   Monotherapy with 
bempedoic acid resulted in very similar effects on lipid profiles to those seen in the studies 
described above [31-33]. LDL-C was reduced by 27.5±1.3% (least-squares mean ± standard error) 
by the 120mg dose. The 180 mg dose resulted in a reduction of 30.1±1.3%. Reductions were also 
seen in apoB, LDL particle number, total cholesterol and non-high-density lipoprotein cholesterol, 
(non-HDL-C).  
In common with previous trials [31-33], use of bempedoic acid was associated with a reduction 
in hsCRP (by 30.1% with 120mg and by 40.2% with 180mg) [37]. Ezetimibe monotherapy was 
also associated with reductions of LDL-C, LDL particle number, total cholesterol and non-HDL 
cholesterol, but in all cases these reductions were smaller than the reductions achieved by 
bempedoic acid, and the differences between the ezetimibe group and the bempedoic acid groups 
were statistically significant. Ezetimibe was associated with an increase in HDL-C of 5.0±1.4%. 
Combined therapy led to greater reductions in LDL-C - 120 mg bempedoic acid + 10 mg ezetimibe 
reduced LDL-C by 43.1±2.6% and 180 mg bempedoic acid + 10 mg ezetimibe by 47.7±2.8% 
(p<0.0001). LDL-C lowering was very similar in subgroups of statin tolerant and statin intolerant 
patients. Similarly, the reductions in LDL particle number, apoB, total cholesterol, non-HDL-C 
were greater in all cases than with either monotherapy treatment arm. This suggests that the 
beneficial effects of ezetimibe and bempedoic acid on LDL-C lowering can be additive. The 
combination of ezetimibe and bempedoic acid 180 mg (n=24) produced a reduction in hsCRP of 
25.6%, while the reduction in hsCRP with bempedoic acid 180 mg (n=100) monotherapy was 
40.2%.  It is unclear if the less robust reduction in hsCRP observed with the combination is due to 
variability of hsCRP in this much smaller treatment arm [35]. The frequency of adverse events 
resulting in discontinuation of study drug was 3.0% for bempedoic acid 120 mg, 6.0% for 
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bempedoic acid 180 mg, 8.0% for ezetimibe, 8.0% for bempedoic acid 120 mg + ezetimibe and 
4.0% for bempedoic acid 180 mg + ezetimibe. As with other safety measures, rates of muscle-
related adverse events were similar across all treatment groups. These results raised no safety 
concerns regarding the use of bempedoic acid [37]. 
 
3.5. Bempedoic acid and statin combined therapy 
The efficacy of combination therapy with statins and bempedoic acid has been investigated in 
two completed studies [35,36] and it is the subject of one ongoing [47] study. A small study (ETC-
1002-007, NCT01779453) was conducted in a patient population taking atorvastatin 10mg at 
baseline and either placebo (n=19) or bempedoic acid titrated up to 240mg/day over 8 weeks 
(n=42) [35]. Compared with placebo, bempedoic acid was associated with an additional reduction 
of LDL-C of 22% (95%CI: 11.4-32.7%). The difference between the groups was statistically 
significant (p=0.0001). With respect to hsCRP, the reduction in the placebo treated group was 9% 
compared to a 23.5% reduction in hsCRP in the bempedoic acid treated patients (p=0.33). No 
safety concerns related to treatment with bempedoic acid were noted [35].  
A larger randomized controlled trial (ETC-1002-009, NCT02072161) investigated the effects 
of 120mg, 180mg of bempedoic acid or placebo in 134 patients who had been treated with one of 
a range of statin regimens atorvastatin 10 or 20 mg, simvastatin 5, 10, or 20 mg, rosuvastatin 5 or 
10 mg or pravastatin 10, 20, or 40 mg for at least 3 months before the trial began [36]. LDL-C was 
reduced by 4.2±4.2% in placebo treated patients and by 17.3±4.0% and 24.3±4.2% in patients 
treated with 120mg and 180mg respectively. These reductions were statistically different than 
placebo at p values of <0.01 and <0.001 respectively. Consistent with previous studies, reductions 
in hsCRP were seen following bempedoic acid treatment (although not statistically significant, 
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hsCRP was unchanged in the placebo and reduced by 21.8% and 29.8% in 120mg [p=0.26] and 
180mg [p=0.08] groups respectively) [36]. Similar, to all the other trials described above, the 
adverse effect profile of bempedoic acid was very similar to the placebo group in this trial [36]. 
 
3.6. Ongoing research  
It has been previously observed that bempedoic acid reduced blood pressure (BP) in a post-hoc 
analysis of patients with mildly elevated blood pressure [31]. A recently completed double blind 
placebo controlled trial (ETC-1002-014, NCT02198098) investigated the effects on LDL-C and 
BP of 180mg bempedoic acid over 6 weeks [34].  Patients treated with 180 mg of bempedoic acid 
had a 21 % reduction in LDL-C (p < 0.0001), and a 24 % reduction as compared to placebo (p < 
0.0001), which increased by 3%. Bempedoic acid reduced hsCRP by 25% from baseline and 44 
% vs placebo (p < 0.0001 for both). There was a neutral effect on blood pressure and no muscle-
related adverse events (AEs) [48]. 
Following observations of an incremental LDL-C lowering effect of bempedoic acid on low 
and moderate dose statin therapy [35,36], an ongoing study (ETC-1002-035, NCT02659397), 
enrolling 60 patients is investigating the safety, pharmacokinetics and pharmacodynamics of 
adding bempedoic acid therapy to high dose (atorvastatin 80mg) statin therapy [47].    
Esperion has also launched a programme of Phase 3 studies called ‘Cholesterol Lowering via 
BEmpedoic acid, an ACL-inhibiting Regimen (CLEAR)’. The first Phase 3 study, CLEAR 
Harmony (ETC-1002-040, NCT02666664) is a multinational double blind study designed to 
investigate the effects of bempedoic acid in patients with high cardiovascular risk and elevated 
LDL-C that is not controlled by maximally-tolerated lipid-modifying therapy. The primary 
endpoint is the frequency of treatment-related adverse effects, and lipid parameters and hsCRP are 
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included as secondary endpoints. 1950 patients will be enrolled in multiple centers in the US and 
Europe, and will receive a daily dose of 180 mg bempedoic acid or placebo. Importantly, this trial 
is recruiting patients with diagnosed ASCVD and/or HeFH, thus it will enable evaluation of 
bempedoic acid in patients at the very highest levels of risk [38].  
Another study - A randomized, double-blind, placebo-controlled study to assess the effects of 
bempedoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or 
at high risk for, cardiovascular disease who are statin intolerant  (ETC-1002-043) will soon be 
initiated [49]. This trial will include approximately 12,600 adult male and female patients ≥18 
years of age with inability to tolerate two or more statins, one at a low dose, due to adverse safety 
effects that started or increased during statin therapy, and resolved or improved when statin therapy 
was discontinued. Low dose statin therapy (LDST) is defined as less than an average starting daily 
dose of rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 
mg, fluvastatin 40 mg, or pitavastatin 2 mg. The investigators assumed that patients who tolerate 
very low dose statin therapy (less than LDST as outlined above) are considered to be intolerant to 
that low dose statin and may qualify for the study. Patients may continue taking very low dose 
statin therapy throughout the study provided that it is stable (used for at least four weeks prior to 
screening) and well tolerated. In this double blind study patients will be randomized 1:1 to either 
bempedoic acid (180 mg) or placebo once daily. The primary objective in this study is to evaluate 
whether long-term treatment with bempedoic acid reduces the risk of major adverse cardiovascular 
events (MACE) in patients with, or at high risk for CVD who are statin intolerant [49]. 
 
4. Conclusion 
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The reduction of LDL-C (as well as non-HDL-C, apoB and total cholesterol) and hsCRP 
demonstrated as monotherapy and in combination with statins and ezetimibe by bempedoic acid 
in phase 2 clinical trials suggest that bempedoic acid has potential for CV risk reduction by 
modulation of both lipids and inflammation. Early results would suggest that this can potentially 
be achieved with a reduced risk of muscle-related adverse events, which might limit the utilization 
and effectiveness of statin therapy. Table 2 is a SWOT analysis relating to the potential use of 
bempedoic acid. A CVOT is planned to determine whether the potential of bempedoic acid is 
realized in the reduction in risk of CV events and death.  
 
5. Expert Opinion 
The effects of bempedoic acid on the lipid profile and other biochemical parameters such as 
hsCRP would suggest that it has the potential to reduce the risk of CVD in a variety of situations 
and in combination with other lipid-lowering agents. Outcomes data are now required in order to 
determine whether CV events are reduced by therapy with bempedoic acid. A planned 
cardiovascular outcome trial (CVOT) will determine the effects of bempedoic acid on the risk of 
CV events and mortality. Previously published trials with bempedoic acid were associated with 
low rates of muscle related adverse effects. Larger clinical studies with bempedoic acid will 
investigate these adverse effects and also assess the incidence of less common adverse events. 
Ongoing and future trials may be able to answer questions that current data cannot. Large well-
powered trials may allow subgroup analyses of the results, such that clinical outcomes can be 
investigated separately in males and females and in different racial groups, in younger and older 
subjects, and in the patients with concrete concomitant conditions. Most studies conducted thus 
far have administered bempedoic acid on a background of statin therapy. A head-to-head clinical 
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trial comparing bempedoic acid against statin therapy, and especially against other lipid lowering 
drugs, which are add-on therapy to statins, would allow a comparison the effects of these drugs on 
lipid markers, hsCRP, and ultimately clinical outcomes. 
If the results of ongoing trials show acceptable results in terms of safety and efficacy, 
bempedoic acid would be well placed to be used as an add-on therapy in patients with lipid profiles 
which are inadequately controlled on standard therapy. The results of the IMPROVE-IT trial have 
demonstrated the clinical benefit of lipid-lowering beyond that which can be achieved by a statin 
alone, and therefore this is an important clinical indication. New therapeutic agents are needed 
because of the dose-limiting adverse effects of statins and other current agents. In this setting, 
bempedoic acid has advantages over PCSK9 inhibitors despite the fact that it does not lower 
plasma cholesterol concentrations to the same extent. Bempedoic acid is bioavailable after oral 
administration, and thus does not require patients to undergo injections. Bempedoic acid is a small 
molecule and manufacture is therefore likely to be less expensive than the PCSK9 inhibitor 
monoclonal antibodies. Bempedoic acid appears to be effective in a multitude of 
hypercholesterolaemic patient types: across a range of triglyceride concentrations, in patients with 
type 2 diabetes mellitus, in patients with hypertension, as monotherapy and in combination with 
statins and with ezetimibe. This versatility may mean that bempedoic acid may prove to be a useful 
addition to lipid-lowering therapy for a large number of patients. 
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* 1 Shepherd 
(1995) 
This study demonstrated the efficacy of pravastatin 
in primary prevention of CVD 
* 2 SSSS Group 
(1994) 
This study demonstrated the efficacy of simvastatin 
in secondary prevention of CVD 
* 4 Baigent (2005) Important meta-analysis demonstrating efficacy of 
lipid-lowering therapy with statins. 
** 5 Cannon (2015) Results of the IMPROVE-IT trial, demonstrating  
benefit of additional lipid lowering therapy in 
patients treated with statins. 
** 14 Banach (2015) This paper provides a clinically-useful definition of 
statin intolerance 
** 20 Pinkosky 
(2016) 
This paper presents detailed complete bempedoic 
acid mechanism of action   
** 42 Thompson 
(2016) 
An excellent overview of adverse effects of statin 
therapy 
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Table 1: Details of completed and ongoing phase 2 and trials with bempedoic acid. 
Esperion 
reference 
1002-003 1002-005 1002-006 1002-007 1002-008 1002-009 1002-014 1002-035 1002-040 
CLEAR 
1000-043 
Completion date 10/2011 10/2012 05/2013 08/2013 11/2014 01/2015 07/2015 Expected 
07/2016 
Expected 
04/2018 
NA 
Clinicaltrals.gov 
registration 
NCT01262638 
 
NCT01607294 NCT01751984 
 
NCT01779453  
 
NCT01941836  
 
NCT02072161 NCT02178098  
 
NCT02659397  NCT02666664 NA 
Literature 
reference 
[29, 30] [31] [32] [34] [36] [35] [33] [46] [37] [48] 
Status Completed Completed Completed Completed Completed Completed Completed Ongoing Ongoing Planned 
Phase 2 2 2 2 2 2 2 2 3 3 
Population HC HC + T2DM HC+ statin 
intolerance 
HC + 
Atorvastatin 
10mg 
HC + ezetimibe 
10mg  
HC + various 
statins 
HC + 
hypertension 
HC + 
atorvastatin 
80mg 
ACVD or FH Intolerance 
of ≥ 2 statins. 
Design Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel group 
trial 
Double blind 
Randomized 
controlled 
parallel 
group trial 
Duration of trial 12 weeks 8 weeks 4 weeks 8 weeks 12 weeks 12 weeks 6 weeks 4 weeks 52 weeks NA 
Bempedoic acid 
daily dose 
40mg  
80mg  
120mg  
80mg 60mg Titrated to 
240mg + 10mg 
atorvastatin 
120mg 
180mg 
120mg + EZE 
180mg+ EZE 
 
120mg + statin 
180mg + statin 
 
180mg 180mg + 
atorvastatin 
80mg 
180mg + statin 
 
180mg + 
background 
therapy 
including 
lipid 
lowering 
drugs. 
Control Placebo Placebo Placebo Placebo + 
10mg 
atorvastatin 
EZE Placebo + statin Placebo Placebo + 
atorvastatin 
80mg 
Placebo + 
Statin 
Placebo+ 
background 
therapy 
including 
lipid 
lowering 
drugs. 
Participants 40mg:     45 
80mg      44 
120mg    44 
Placebo   44 
80mg      30 
Placebo   30 
60mg       37 
Placebo   19 
240mg   42 
Placebo 16 
120mg               
99 
180mg               
100 
120mg + EZE   
26 
180mg+ EZE    
24 
EZE                  99  
120mg + statin    
43 
180mg + statin    
45 
Placebo + statin   
45 
Total = 143 Estimated total 
= 60 
Estimated total 
= 1950 
Estimated 
total = 
12,600 
% males 40mg:     42 
80mg      52 
120mg    57 
Placebo   70 
80mg      57 
Placebo   67 
60mg      54 
Placebo   42 
NA 120mg               
46 
180mg               
49 
120mg + EZE   
46 
180mg+ EZE    
46 
EZE                  48 
120mg + statin    
39 
180mg + statin    
31 
Placebo + statin   
51 
NA NA NA NA 
Baseline BMI, 
kg/m2 
40mg:     27±4 
80mg      29±4 
120mg    28±3 
Placebo   29±3 
80mg      31±3 
Placebo   29±3 
60mg      30±4 
Placebo   29±5 
NA 120mg               
31±6 
180mg               
31±5 
120mg + EZE   
30±5 
180mg+ EZE    
28±5 
EZE                  
30±5 
120mg + statin    
30±6 
180mg + statin    
30±6 
Placebo + statin   
31±6 
NA NA NA NA 
Baseline LDL-C, 
mg/dl  
40mg:     
163±25 
80mg      170±26 
120mg    
165±23 
Placebo   
167±22 
80mg      
125±28 
Placebo   
128±29 
60mg      176±37 
Placebo   
185±33 
240mg   107±5 
Placebo 104±7 
120mg               
164±28 
180mg               
166±24 
120mg + EZE   
162±26 
180mg+ EZE    
167±27 
EZE                  
165±25 
120mg + statin    
134±20 
180mg + statin    
142±28 
Placebo + statin   
131±22 
NA NA NA NA 
Baseline TC, 
mg/dl 
40mg:     
249±33 
80mg      252±31 
120mg    
248±25 
Placebo   
250±26 
80mg      
206±36 
Placebo   
207±34 
60mg      263±45 
Placebo   
276±43 
NA 120mg               
249±31 
180mg               
253±33 
120mg + EZE   
247±35 
180mg+ EZE    
246±32 
EZE                  
248±32 
120mg + statin    
216±24 
180mg + statin    
229±29 
Placebo + statin   
212±24 
NA NA NA NA 
Baseline HDL-C, 
mg/dl 
40mg:     57±14 
80mg      50±12 
120mg    51±12 
Placebo   49±11 
80mg      44±10 
Placebo   47±12 
60mg      51±14 
Placebo   58±18 
NA 120mg               
54±16 
180mg               
52±13 
120mg + EZE   
51±15 
180mg+ EZE    
52±16 
EZE                  
49±12 
120mg + statin    
55±15 
180mg + statin    
55±14 
Placebo + statin   
54±14 
NA NA NA NA 
Baseline 
triglycerides 
mg/dl 
40mg:     
148±66 
80mg      158±68 
120mg    
159±74 
Placebo   
168±79 
80mg      182‡ 
Placebo   152‡ 
60mg      
200±172 
Placebo   
166±72 
NA 120mg               
136‡ 
180mg               
162‡ 
120mg + EZE   
161‡ 
180mg+ EZE    
151‡ 
EZE                  
163‡ 
120mg + statin    
112‡ 
180mg + statin    
145‡ 
Placebo + statin   
119‡ 
NA NA NA NA 
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Baseline 
Lipoprotein (a), 
mg/dl 
40mg:     32±35 
80mg      29±28 
120mg    24±25 
Placebo   30±29 
NA NA NA NA NA NA NA NA NA 
Baseline hsCRP 
mg/l 
40mg:     1.8‡ 
80mg      1.9‡ 
120mg    1.4‡ 
Placebo   1.8‡ 
80mg      2‡ 
Placebo   2‡ 
60mg      2.2‡ 
Placebo   1.6‡ 
NA 120mg               
1.6‡ 
180mg               
2.5‡ 
120mg + EZE   
1.8‡ 
180mg+ EZE    
1.3‡ 
EZE                  
2.6‡ 
120mg + statin    
1.8‡ 
180mg + statin    
1.8‡ 
Placebo + statin   
1.8‡ 
NA NA NA NA  
Baseline glucose 
mg/dl 
40mg:     95±10 
80mg      97±7 
120mg    94±9 
Placebo   97±11 
80mg      
186±27 
Placebo   
198±32 
NA NA NA NA NA NA NA NA 
Baseline SBP, 
mmHg 
40mg:     
119±11 
80mg      121±9 
120mg    119±9 
Placebo   123±9 
80mg      
117±10 
Placebo   
120±13 
NA NA 120mg               
126±11 
180mg               
125±12 
120mg + EZE   
126±12 
180mg+ EZE    
126±11 
EZE                  
119±12 
120mg + statin    
128±11 
180mg + statin    
129±14 
Placebo + statin   
126±12 
NA NA NA NA 
Baseline DBP, 
mmHg 
40mg:     73±8 
80mg      78±6 
120mg    76±6 
Placebo   78±7 
80mg      77±6 
Placebo   78±6 
NA NA 120mg               
77±8 
180mg               
78±7 
120mg + EZE   
77±7 
180mg+ EZE    
76±9 
EZE                  
78±7 
120mg + statin    
80±8 
180mg + statin    
78±9 
Placebo + statin   
78±7 
NA NA NA NA 
% Change LDL-
C ! 
40mg:     -
18±2**** 
80mg      -
25±2**** 
120mg    -
27±2**** 
Placebo   -
2±2**** 
80mg      -
43±3**** 
Placebo    -4±3 
60mg    -
32±2**** 
Placebo  -3±3 
240mg   -
22±3**** 
Placebo    0±5 
120mg               -
28±1** 
180mg               -
30±1**** 
120mg + EZE   -
43±3**** 
180mg+ EZE    -
48±3**** 
EZE                  -
21±1 
120mg + statin    
-17±4 
180mg + statin    
-24±4** 
Placebo + statin    
-4±4**** 
NA NA NA NA 
% Change TC ! 40mg:     -12±2* 
80mg      -18±2* 
120mg    -17±2* 
Placebo   -1±2 
80mg      -
25±2**** 
Placebo    -1±2 
60mg    -
22±2**** 
Placebo -4±2 
NA 120mg               -
19±1** 
180mg               -
21±1**** 
120mg + EZE   -
31±2**** 
180mg+ EZE    -
34±2*** 
EZE                  -
14±1 
120mg + statin    
-13±3 
180mg + statin    
-15±3** 
Placebo + statin    
-3±3** 
NA NA NA NA 
% Change HDL 
! 
40mg:     7±2 
80mg      1±2 
120mg    4±2 
Placebo   2±2 
80mg      -1±2 
**** 
Placebo   -1±2 
60mg      -8±3 
Placebo   -2±4 
NA 120mg               -
6±1**** 
180mg               -
5±1**** 
120mg + EZE   -
3±3* 
180mg+ EZE    
4±3** 
EZE                  
5±1 
120mg + statin   
-6±3 
180mg + statin   
-4±3 
Placebo + statin  
-2±3 
NA NA NA NA 
% Change 
hsCRP ! 
40mg:     -21‡ 
80mg      -26‡ 
120mg    -20‡ 
Placebo   -2‡ 
80mg      -41** 
Placebo   -11 
60mg      -42‡** 
Placebo   0‡ 
240mg   -24 
Placebo  -9 
120mg               -
30** 
180mg               -
40** 
120mg + EZE   -
38 
180mg+ EZE    -
26* 
EZE                  -
10 
120mg + statin    
-22 
180mg + statin    
-30 
Placebo + statin   
0 
NA NA NA NA 
 
Values are reported as mean ± SD unless otherwise stated; !Least squares mean ± SEM ‡Median;*p<0.05 v control , 
**p<0.01 v control, ***p<0.001 v control, ****p<0.0001 v control 
Abbreviations: CLEAR: Cholesterol Lowering via ETC-1002, an ACL-inhibiting Regimen; ACVD, atherosclerotic 
cardiovascular disease; FH, familial hypercholesterolaemia; HC, hypercholesterolaemia; NA, not available; SBP, 
diastolic blood pressure; DBP, diastolic blood pressure; EZE = 10mg ezetimibe 
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Table 2: SWOT analysis relating to the potential use of bempedoic acid. 
Strengths  Orally bioavailable 
 Prodrug is activated only at site of action in liver, reducing potential for 
adverse effects 
 Demonstrated LDL-C and hsCRP lowering 
 No indication of adverse effects 
 Appears to be effective in diverse populations 
Weaknesses  No data yet available on hard clinical outcomes 
Opportunities  Combination therapy with statins or ezetimibe 
 Lipid-lowering in statin-intolerant patients 
 Potential for use in familial hypercholesterolaemia 
 Planned outcomes study 
Threats  Possibility that bempedoic acid will not show benefit in outcomes trials 
 Possibility of emergent idiosyncratic adverse effect in clinical trials 
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FIGURE LEGENDS: 
Figure 1: Bempedoic acid (ETC-1002) is converted to ETC-1002-CoA by ACSVL1. ETC-1002-
CoA inhibits ACL and therefore reduces downstream production of cholesterol and fatty acids by 
the mevalonate pathway.  
*Abbreviations: ACC, acetyl-coA carboxylase; ACL, Adenosine triphosphate-citrate lyase; HMG-CoA, Hydroxy-
methyl-glutaryl-coenzyme A; HMGCR, Hydroxy-methyl-glutaryl-coenzyme A reductase. 
 
 
 
 
 
 
